Scalable Production of HPV16 L1 Protein and VLPs from Tobacco Leaves by Zahin, Maryam (Author) et al.
RESEARCH ARTICLE
Scalable Production of HPV16 L1 Protein and
VLPs from Tobacco Leaves
Maryam Zahin1, Joongho Joh1,2*, Sujita Khanal1,3, Adam Husk1,4, Hugh Mason5,
Heribert Warzecha6, Shin-je Ghim1, Donald M. Miller1,2, Nobuyuki Matoba1,4,7, Alfred
Bennett Jenson1
1 James Graham Brown Cancer Center, University of Louisville, Louisville, Kentucky, United States of
America, 2 Department of Medicine, University of Louisville, Louisville, Kentucky, United States of America,
3 Department of Biochemistry and Molecular Genetics, University of Louisville, Louisville, Kentucky, United
States of America, 4 Owensboro Cancer Research Program, Owensboro, Kentucky, United States of
America, 5 Biodesign Institute and School of Life Sciences, Arizona State University, Tempe, Arizona,
United States of America, 6 Plant Biotechnology and Metabolic Engineering, Technische Universita¨t
Darmstadt, Schnittspahnstrasse 3–5, 64287, Darmstadt, Germany, 7 Department of Pharmacology and
Toxicology, University of Louisville, Louisville, Kentucky, United States of America
* j0joh001@louisville.edu
Abstract
Cervical cancer is the most common malignancy among women particularly in developing
countries, with human papillomavirus (HPV) 16 causing 50% of invasive cervical cancers. A
plant-based HPV vaccine is an alternative to the currently available virus-like particle (VLP)
vaccines, and would be much less expensive. We optimized methods to express HPV16 L1
protein and purify VLPs from tobacco (Nicotiana benthamiana) leaves transfected with the
magnICON deconstructed viral vector expression system. L1 proteins were extracted from
agro-infiltrated leaves using a series of pH and salt mediated buffers. Expression levels of
L1 proteins and VLPs were verified by immunoblot and ELISA, which confirmed the pres-
ence of sequential and conformational epitopes, respectively. Among three constructs
tested (16L1d22, TPL1d22, and TPL1F), TPL1F, containing a full-length L1 and chloroplast
transit peptide, was best. Extraction of HPV16 L1 from leaf tissue was most efficient (>
2.5% of total soluble protein) with a low-salt phosphate buffer. VLPs were purified using
both cesium chloride (CsCl) density gradient and size exclusion chromatography. Electron
microscopy studies confirmed the presence of assembled forms of HPV16 L1 VLPs. Collec-
tively; our results indicated that chloroplast-targeted transient expression in tobacco plants
is promising for the production of a cheap, efficacious HPV16 L1 VLP vaccine. Studies are
underway to develop plant VLPs for the production of a cervical cancer vaccine.
Introduction
Over 95% of cervical cancers are caused by human papillomaviruses (HPVs). Cervical cancer is
the second most common HPV-associated cancer in women, with approximately one-half mil-
lion new cervical cancer cases and almost 250,000 deaths each year worldwide [1]. The greatest
burden of HPV-induced cancers occurs in developing countries. Seventy-five percent of
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cervical cancers are caused by two HPV types, 16 and 18. HPV16 is also responsible for the
majority of anal, penile, vaginal, vulvar, and oropharyngeal cancers [2].
The major recombinant HPV vaccines, Gardasil and Cervarix, are composed of major cap-
sid proteins of HPV which self-assemble into highly immunogenic VLPs in vitro and in vivo
with either T = 7 symmetry, identical to native virions, or T = 1 comprised of 12 capsomers [3–
5]. Three VLP-based vaccines have been approved by the FDA to prevent HPV infection: Gar-
dasil (4 HPV types), Gardasil 9 (9 HPV types), and Cervarix (2 PV types). All three vaccines
are effective in preventing infection of the HPV types represented in the vaccines and conse-
quently premalignant/malignant disease [6]. Although these commercial vaccines are highly
immunogenic, well tolerated, and efficacious, the associated high production and distribution
costs have been challenging, particularly for those living in developing countries. To date, no
affordable HPV vaccine that can meet the clinical need for under-served populations is avail-
able. Therefore, the need for inexpensive and efficient expression systems for production of
recombinant proteins has focused the attention of researchers and entrepreneurs on plants as
the cheapest potential production hosts.
Plants have emerged as an alternative biotechnological means of producing pharmaceutical
[7] and therapeutic proteins [8], with VLPs being the most important candidate vaccines pro-
duced in plants [9,10]. Plant-produced VLPs offer many advantages in terms of safety, immu-
nogenicity, and antigen stability together with their cost-effectiveness and scalable production
benefits [9]. Research into the development of an effective HPV vaccine using plants has been
initiated in several laboratories, including ours, and L1 proteins have been successfully expressed
[11–13]. However, all of these studies resulted in very low expression levels of the L1 protein
(<1%), except for Maclean et al. [14], who reported the accumulation of L1 that was 11% of total
soluble protein (TSP) when the chloroplast signal peptide fused with L1 and formed VLPs in the
chloroplasts of plant cells. Since then, various vaccine antigens have been targeted and success-
fully expressed in chloroplasts, including HPV16 VLPs, at levels up to 24% of TSP [13,15]. It is
assumed that greater expression of vaccine antigens in chloroplasts is the result of large gene
copy numbers in the plastid genome, or higher stability of proteins in this organelle compared
with that of proteins in the cytoplasm or other subcellular compartments [16]. Chloroplast-pro-
duced VLPs were reported to be immunogenic in mice and exhibited an effective neutralizing
response. However, because of the lack of optimized purification protocols for recovering the
intact VLPs, vaccine yield has been low and challenging for clinical trials [17,18].
Another challenge is the chromatographic purification of plant-based proteins. It has been
demonstrated that different physiological conditions, together with extraction and purification
processes, play a crucial role in denaturation of recombinant protein and determination of
yield, stability, and biological activity [19]. CsCl and sucrose gradient methods have been used
for purifying L1 VLPs from tobacco plants [13,15]. These methods are cost-intensive and unre-
liable for industrial and clinical settings. Therefore, it is assumed that chromatographic purifi-
cation would be the best method to purify L1 VLPs from tobacco plants. Recently, Kim et al.
[19] conducted an extensive analysis to purify HPV16 L1 protein from yeast cells using a chro-
matography system. However, no optimized protocol has been reported for the chro-
matographic purification of HPV16 L1 VLPs from tobacco plants.
In this study, to express and purify HPV16 L1 VLPs from tobacco plants, we re-designed
our expression construct and addressed major shortcomings from previous plant research,
including the low yield and less than optimized purification procedures of earlier plant-based
technologies. Our improved conditions for HPV16 L1 production in tobacco plants (Nicotiana
benthamiana) use a high-efficiency binary vector system with a chloroplast signal sequence to
assemble the HPV L1 proteins in chloroplasts. The yield of purified plant VLPs was high and
antigenically similar to VLPs produced in the baculovirus expression system (Cervarix). Using
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DPI, days post infiltration; TSP, total soluble protein;
MoAb, monoclonal antibody; PoAb, polyclonal
antibody.
simple purification steps, this is possibly the first report to present high yield of intact HPV16
L1 VLPs from tobacco plants. We anticipate that our isolated VLPs are safe and can be used as
an affordable vaccine worldwide.
Materials and Methods
Construction of Vectors
We designed a plant codon-optimized coding sequence for HPV 16 L1 (505 amino acids)
based on a strain isolated at the University of Rochester Medical Center (Robert Rose), which
is nearly identical to Genbank accession ACV53978.1, except for the occurrence of Ser in place
of Thr at position 389. Codons were chosen to optimize expression in tobacco, and avoiding
spurious mRNA processing signals [20]. The C-terminal truncation to remove 22 amino acids
and add a stop codon and BamHI site was obtained by PCR with the end-tailoring primer
16L1d22-Bam-R (5’–GGGGATCCTTATCCTAATGTGAACTTTGGCTT). For chloroplast
targeting, a 59 amino acid plastid peptide (TP) coding sequence from rbcS was fused to the ini-
tiation codon of the L1 gene using overlap extension PCR. The plastid targeting sequence was
amplified from pICH12190 (Icon Genetics GmbH, Halle, Germany) using the primers TP-
Xho-F (5’-CCCTCGAGAACAATGGCTTCTTCTATGCTTTCTTC) and TPL1-OL-R (5’-GA
AGGGAGCCAAAGAGACATGCATTGGACTCTTCCTCCGT), while the 5’ end of the L1
gene was amplified using primers TPL1-OL-F (5’- ACGGAGGAAGAGTCCAATGCATGT
CTCTTTGGCTCCCTTC) and 16L1-447-R (5’- CACAACTGTGTTTGCTTGTAATCC). The
two overlapping fragments were mixed and amplified using the terminal primers TP-Xho-F
and 16L1-447-R, and the resulting product was digested with XhoI and NcoI and ligated with
pIBT210.1 [20], digested likewise to produce pTPL1-210. The TPL1 segment was fused to the
3’ end of the L1 gene by ligation at the NcoI site. The L1 genes were end-tailored by PCR with
BsaI sites to allow insertion into pICH26212 (Icon Genetics), yielding p26212-16L1d22 (483 aa
L1, cytosol-targeted), p26212-TPL1d22 (483 aa L1, chloroplast targeted), and p26212-TPL1F
(505 aa L1, chloroplast targeted).
The E. coli and Agrobacterium transformed plasmid DNA was confirmed for integration
using BamHI and XhoI restriction digestion analysis and the PCR amplification method. The
set of primers used were MZ-1L (5'-GCAGGTGTGGTTGACGAAT-3') and MZ-1R (5'-
CAAACGTGCGTTAACAGGTG-3') (Integrated DNA technologies, USA) for amplification
of N- and C- termini of the target gene, respectively.
Electroporation and Agrobacterial transformation
Initially, A. tumefaciens (GV3101) cells were made electro-competent [21], and 50 μL of cells
were mixed with 50–200 ng of the purified respective HPV16 L1 DNA in a 1.0 mm gap electro-
poration cuvette (Molecular Bio Products, USA). The cells were transformed using a GenePul-
ser (BioRad, USA) with a setting of 2000V for 5 ms. Electroporated cells (51 μL) were
immediately added to 1 mL YenB broth (yeast extract and nutrient broth, pH 7.0) containing
Kanamycin (50 μg mL-1) and incubated with shaking for 1 h and then plated onto YenB media
containing appropriate antibiotics.
Infiltration of tobacco leaves
Agro-infiltration of tobacco leaves was completed with transformed Agrobacterium cultures
containing integrated HPV16 L1 genes. Cultures were grown from starter cultures with shaking
at 28°C to attain the exponential phase (optical density at 600 nm [OD600]; 0.6 to 0.8) in YenB
broth containing the appropriate antibiotics. The bacteria were pelleted down by centrifugation
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at 3000×g for 10 min, suspended in infiltration buffer (10 mMMES and 10 mMMgSO4, pH
5.5). Final OD600 after centrifugation and resuspension was 0.1. The vacuum infiltration tech-
nique was employed to infiltrate 2–4 week old leaves of N. benthamiana plants. Following infil-
tration, the plants were grown for 1–9 days post infiltration (DPI) under conditions of 16 h
light, 8 h dark at 23°C.
Preparation of leaf extract
In the preliminary analysis, 200 mg of tobacco leaves were harvested at 6 DPI and proteins
were extracted using HEPES buffer as described [13]. For time point analysis, 200 mg of fresh
tobacco plant leaves were harvested at 3–9 DPIs and homogenized at the ratio of 1:2 in relation
to the volume of respective buffers (400 μL; pH 2–8 with or without 0.1 M NaCl and 40 mM
ascorbic acid) in a Stormblender (Bullet blender Storm 24, Next Advance, USA) to extract the
best proteins. The lysates were clarified at (14,000×g) for 10 min at 4°C. The supernatant col-
lected after clarification was used for further analysis.
SDS-PAGE and Immunoblot analysis
The extracted soluble protein samples (supernatant) collected from homogenized and clarified
tobacco leaves were mixed with sodium dodecyl sulfate (SDS) loading buffer (20% glycerol, 4%
SDS, 100 mM Tris, pH 6.8, 0.002% bromophenol blue), and heated at 95°C for 5 min. These
proteins were separated on SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electropho-
resis) gels (NUPAGE 4–12% Bis-TRIS, Invitrogen, USA). Gels were either stained with coo-
massie blue (SimplyBlue SafeStain; Invitrogen, USA) or transferred to a PVDF membrane
(Immobilon-P transfer membrane, EMDMillipore, USA) and saturated with 5% milk in Tris-
buffered saline and Tween (TBST) for 1 h. The membrane was then incubated overnight at 4°C
with HPV16 L1 specific monoclonal (16E, in-house) or polyclonal (disCPV2, in-house) anti-
bodies with 3% milk/TBST (Tris and NaCl containing 0.1% Tween 20). The membrane was
washed three times with TBST and finally incubated with 1:5000 diluted secondary antibody
(peroxidase conjugated goat anti-mouse IgG, Thermo Scientific Pierce, USA). Proteins were
detected by chemiluminescence (SuperSignal West Dura Extended Duration Substrate;
Thermo Scientific Pierce, USA) and bands were visualized on x-ray film (CL-XPosure Film,
Thermo Scientific Pierce, USA) using an SRX-101A processor (Konica Minolta Medical Imag-
ing USA, Inc). Baculovirus-infected insect cell VLPs made in-house was used as a positive con-
trol. The purified fractions from CsCl, ammonium sulfate (AMS), size exclusion
chromatography (SEC), and ion-exchange chromatography (IEC) fractions were also analyzed
for protein expression, as described above.
Antibodies
16A and C are murine monoclonal antibodies made in the laboratory against intact virus-like
particles and characterized [22] whereas 16E was generated to detect sequential epitopes of L1,
using wild type HPV16 (antigen produced in insect cells), respectively. DisCPV2 is a rabbit
polyclonal antibody made against disrupted canine papillomavirus produced using xenograph
system. 1H8 is the broad spectrum mouse monoclonal HPV antibody which was produced
against SDS-disrupted bovine papillomavirus type 1 (BPV1) and used to identify the product
of the L1 open reading frame (ORF) of BPV1. IH8 was found to be reactive with purified major
capsid protein (L1) and known to detect the FGA epitope of both BPV1 and HPV16,
respectively.
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ELISA
The ELISA was performed on all homogenized, purified leaf extracts and sera collected from
immunizing mice as described in sections 2.4, 2.5 and 2.14. The 96-well ELISA plates (Immu-
nolon 2; Dynatech) were coated overnight at 4°C with 100 μL of plant extracts or 500 ng per
well of purified plant VLPs re-suspended in 1X Dulbecco's phosphate-buffered saline (DPBS).
500 ng of baculovirus-infected insect cell VLPs were loaded as a positive control. The plates
were washed three times with washing buffer (PBS-T) and blocked with 5% BSA in 1XPBS
(PBSA) for 1 h at 37°C. After washing three times, plant extracts coated plates were incubated
with monoclonal or polyclonal antibodies against HPV16 L1 conformational or sequential epi-
topes, at a dilution of 1:1000 in 1% PBSA for 1 h at 37°C. Similarly, the purified plant VLPs
coated plates were reacted with collected mouse sera, at a dilution of 1:100 in 1% PBSA for 1 h
at 37°C. Moreover, to test the immunogenicity of plant derived VLPs, pooled mice sera were
diluted 4-fold in 1% PBSA (1:50–1:51200) and titrated against 500 ng of insect cell derived
VLPs. Thereafter, plates were washed thrice with PBS-T, and incubated with respective alkaline
phosphatase-conjugated goat anti-mouse or anti-rabbit IgG (H + L) (Sigma, USA) at a dilution
of 1:5000 in 1% PBSA for 1 h at 37°C. Unbound secondary antibodies were removed by wash-
ing and bound antibodies were stained with an alkaline phosphatase chromogenic substrate
(Sigma, USA), and absorption was measured at 405 nm. One percent PBSA and sera collected
from unimmunized mice were used as negative controls for the background reaction.
Protein purification by cesium chloride density gradient
ultracentrifugation
Freshly harvested tobacco leaves (5 g) were grounded in liquid N2 and homogenized with
extraction buffer (PBS with 40 mM ascorbic acid, pH 7.0). The lysate was centrifuged at
(14,000×g) for 30 min at 4°C. The cleared supernatant was collected and mixed with cesium
chloride (CsCl) solution to a concentration of 1.31 g mL-1 as determined using a refractometer
(Leica Mark II, Reichert-Jung) and centrifuged at (122,800×g) for 20 h. The bands on CsCl gra-
dients were collected, their densities measured, and the CsCl solution was replaced with
1XDPBS containing CaCl2 and MgCl2 (Life Technologies) by dialysis. The dialyzed sample was
again centrifuged for 2 h at the same speed to pellet down the VLPs, which were then sus-
pended in a minimal amount of 1XDPBS for storage at -80°C until analysis.
Ammonium sulfate precipitation and removal of contaminated proteins
To remove contaminants from L1 proteins, ammonium sulfate precipitation was conducted as
previously described [19]. The precipitated protein was pelleted down at (23,700×g) for 10 min
at 4°C. The pelleted protein was re-suspended with PBS+ 0.01% Tween 20, and the re-sus-
pended solution was stored at 4°C.
To remove further contaminants, the ammonium sulfate precipitate was dialyzed against
PBS + 0.01% Tween 20 [19]. Using the previously described method [19], the precipitated pro-
tein was removed by centrifugation at (23,700×g) for 10 min. The obtained supernatant was
used for the purification process.
Ion exchange chromatography
The supernatant obtained after ammonium sulfate precipitation was dialyzed against the bind-
ing buffer (PBS containing total 0.1 M NaCl, pH 7.2 + 0.01% Tween 20) for 3 h at 4°C. The 5
mL cation exchange column (Hitrap sepharose [CMFF], GE Healthcare Life Sciences, USA)
was used to purify the L1 protein. The column was equilibrated with binding buffer, and the
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dialyzed sample (5 mL) was loaded onto the column. The column was then washed with five
column volumes of binding buffer with a flow rate of 0.4 mL min-1, followed by the elution
buffer PBS containing 2.0 M NaCl (salt gradient) and 0.01% Tween 20. The total run lasted 1.5
h. The fractions corresponding to peaks were pooled and dialyzed against binding buffer and
concentrated with an additional 2-h centrifugation step (122,800×g).
Size exclusion chromatography
SEC was performed on dialyzed plant VLPs purified by the CsCl density gradient ultracentrifu-
gation method and ammonium sulfate precipitation. Dialyzed samples were loaded on (16/
600) Superdex column (Hitrap, GE Healthcare Life Sciences, USA). The running buffer for this
column was PBS, pH 7.2, 0.01% Tween 20. Fractions were collected from the column at 0.5 mL
min-1 for 4 h; their absorbance at 280 nm was measured with a spectrophotometer, and
HPV16 L1 protein was analyzed by SDS–PAGE and immunoblotting, as described above.
Determination of protein concentration
Total protein concentration of each VLP preparation and ammonium sulfate precipitated sam-
ples was determined using a Nanodrop ND-8000 (Thermo Scientific, USA) at 280 nm and the
Bio-Rad Bradford protein assay reagent (Bio-Rad Laboratories, USA) with bovine serum albu-
min (BSA; Pierce, USA) as a standard. The yield of L1 protein was quantified using SDS-PAGE
analysis. Serially diluted HPV16 L1 VLPs from leaves and insect cells were loaded on an
SDS-PAGE gel, and their band densities were measured by Quantity one image analyzer (ver-
sion 4.5, Bio-Rad).
Electron microscopy
The dialyzed, concentrated and purified HPV16 L1 VLPs were absorbed onto carbon-coated
grids (Electron Microscopy Sciences, USA) and negatively stained with 2% phosphotungstic
acid (pH 6.8). The quality of VLPs was examined at a final magnification of 41,000× by trans-
mission electron microscopy (Phillips CM-12).
Mice
C57BL/6J mice were obtained from the Jackson Laboratory (Bar Harbor, ME).
Only female mice were used to minimize fighting. Mice were maintained in humidity-, tem-
perature-, and light cycle (12:12) controlled vivarium under specific pathogen-free conditions.
Mice were housed in double-pen polycarbonate cages (330 cm2 floor area) at a maximum
capacity of four mice per pen. Mice were allowed free access to autoclaved food (NIH 31, 6%
fat; Lab Diet 5K52, Purina Mills, St. Louis, MO) and acidified water (pH 2.8–3.2). Mice were
euthanized using CO2 in a chamber fitted with an appropriate pressure-reducing regulator and
flow meter or equivalent equipment to ensure a gradual displacement of 10–30% volume/min-
ute. All studies were done with the University of Louisville, Institutional Animal Care and
Use Committee (approval number #13051) and Biosafety Committee (approval number IBC
#10–024) approvals.
Mouse immunization
In order to collect hyperimmune sera of plant VLPs, C57BL/6J wild-type mice were immunized
as previously described [23]. Hundred μg of purified plant VLPs were prepared for each injec-
tion without any adjuvant application and administered intraperitoneally to C57BL/6J mice for
three times at 2 weeks of interval. Blood was drawn from unimmunized (control) and
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immunized mice and sera were separated by centrifugation at 3,000 rpm for 10 min and stored
at 4°C.
Statistical analysis
All statistical analyses were performed with GraphPad Prism statistical software (version 4.03;
La Jolla, CA). Statistical differences were determined by Student's t-test and one was ANOVA.
Differences were considered to be statistically significant if the p-value was 0.05.
Results
Infiltration of tobacco plants with HPV16 L1 DNA
Three constructed vectors p26212-16L1d22, p26212-TPL1d22, and p26212-TPL1F for protein
expression in plants were designated as V1, V2, and V3, respectively (Fig 1A). Restriction
digestion and PCR amplification profiles were determined in Fig 1B and 1C, respectively.
Expression of HPV16 L1 protein
Three steps were followed to optimize the expression level of the L1 protein. At first, the
expression level of the L1 protein in plants by different expression vectors was confirmed at 6
DPI. Extracted L1 proteins (L1d22, TP+L1d22, and TP+L1F) were detected at target size of 51
or 56 kDa when compared with baculovirus-infected insect cells used as a positive control (Fig
2A). Although no target L1 protein was detected using monoclonal antibody (16E), the L1
Fig 1. Diagrammatic presentation of constructed protein expression vectors for transformation of
Agrobacterium and plants. (A) Pictorial representation of constructed vectors. Restriction digestion profile of
cloned plasmids DNAs (V1, V2, and V3) from E. coli (Lane 1–3) (B) and PCR amplifications of transformed E. coli
(Lane 1–3) and Agrobacterial cells (Lanes 4–6), (C), respectively Target DNAs (1.5 and 1.7 Kbs) were found on 1%
agarose gel when compared with DNAmolecular weight marker (Lane M, 1 kb DNA ladder, Invitrogen).
doi:10.1371/journal.pone.0160995.g001
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protein from p26212-TPL1F (V3) vector was extracted at the highest level among the three
constructs using polyclonal antibody (disCPV2).
Secondly, to optimize and characterize the purification condition for the L1 protein
extracted from infiltrated plant leaves, different physiological buffers with various pH (2–8),
ascorbic acid supplement, and salt (0 and 0.1 M) were used. Proteins were successfully detected
in crude extracts homogenized with pH 4 to 8 buffers, and higher concentrations were found
in the presence (0.1 M) rather than the absence of salt containing buffers (Fig 2B). Overall, the
neutral phosphate buffer (pH 7) with (0.1 M) salt was chosen as the best extractable solvent.
Among these three constructs, V3 was highly extracted and selected for further experiments.
Thirdly, a time point study was conducted to determine the optimal duration of protein
expression in V3 transformed tobacco plants. Interestingly, the expression levels of the L1s
were high at 5 to 9 DPIs, whereas non-infiltrated control leaves were negative for all the tested
antibodies (S1 Fig). The protein was expressed maximally at 7 DPI, and it decreased as depicted
in Fig 2C. Moreover, the highest expression of epitopes was found in sample extracts between 6
and 7 DPI plants (Fig 2D).
Based on obtained results, 6 DPI leaves transformed with V3 vector and extracted with neu-
tral PBS buffer was chosen for further purification and quantification studies. Compared with
purified VLPs from insect cells,>2.5% of TSP for L1 proteins (2.5 μg L1 / 100 μg TSP) was cal-
culated and overall, 250 mg of L1 yield was obtained per kg of plant biomass.
Fig 2. The detection profile and quantification analysis of L1 protein extracted from transformed tobacco
plants. The immunoblots represent the HPV16 L1 detection profile of different vector-infiltrated plants extracted
with (A) HEPES buffer, (B) using different physiological conditions with pH 2–8 in the presence (WS) or absence of
salt (NS), (C) extraction of HPV16 L1 protein with PBS buffer at 5–9 days post infiltration (DPI) from plant leaves
infiltrated with construct (TPL1F; V3). Antibodies, MoAb-16E and PoAb- disCPV2 were used for immunoblots. The
positive control (PC) was disrupted VLPs from insect cells and arrows in immunoblots show HPV L1 band at 56
kDa. (D) Bar diagram of ELISA for VLPs extracted from crude plant extract (V3) at 5–9 DPIs. MoAbs-16 A, C and E
and PoAb-R intact were used to detect specific sequential and conformational epitopes of HPV16 L1 and VLPs
from insect cells were used as a positive control (PC). Student’s t-test was done to compare VLPs from plant
extract at 5–9 DPIs with VLPs from insect cells. *p < 0.05; **p <0.01 and ***p <0.001.
doi:10.1371/journal.pone.0160995.g002
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Purification of HPV16 VLPs
When crude extracts were purified using CsCl gradient centrifugation, two bands were visual-
ized at approximately 1.29 g/cm3 density in centrifuge tubes and were referred to as the top
and lower bands. L1 proteins were detected in both the collected bands, however, a relatively
stronger signal was identified from the top collected band than the lower one (Fig 3A). In addi-
tion, the presence of conformational epitopes on the VLP's matrix was analyzed by ELISA
assay and compared between the two collected band samples (data not shown). The results
showed that top collected band displayed higher ELISA signals than the lower band, suggesting
more accumulation of VLPs in the top band.
In order to remove residual contaminants and clarify the high molecular size of VLPs, the
dialyzed top band of L1 was further subjected to size exclusion (SEC) column. Differently
assembled forms of L1 VLPs were eluted in a peak with an elution volume of approximately 42
mL of running buffer between 2000 and 75 kDa when compared with different molecular
weight protein standards (Fig 3B). L1 proteins with approximately 56 kDa size (Fig 3C) were
Fig 3. Purification profile of V3 infiltrated tobacco plants. (A) Immunoblot showing the target L1 protein
collected from CsCl density gradients top (TB) and lower bands (LB) from V3 infiltrated plants. (B) The size
exclusion chromatogram of CsCl collected and dialyzed V3 sample on 16/600 superdex-200 prep grade column
using FPLC system. The molecular standards represented on the chromatogram are BD; bluedex (2000 kDa), C;
conalbumin (75 kDa), O; ovalbumin (43 kDa). (C) SDS-PAGE and immunoblot showing the L1 band of dissociated
chromatographic purified VLPs. The VLPs from insect cells were used as loading positive control and arrows in
immunoblots show HPV L1 band at 56 kDa; 16E was used as HPV16 L1 sequential epitopes detecting monoclonal
antibody. (D) ELISA profile for characterization of plant purified HPV16 VLPs using monoclonal (16A, C, and E) and
polyclonal (R intact) in-house antibodies. 16A and C detect conformational epitopes, whereas 16E and R intact
detect both conformational, as well as sequential epitopes. (E) Validation of purified VLPs by immunoblot using the
same sequential and conformational antibodies as described in D. One way analysis of variance (ANOVA) was
done to appreciate the dose response and a value *p < 0.05 was considered significantly different.
doi:10.1371/journal.pone.0160995.g003
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detected from the pooled fractions (#44–54) of SEC. collected fractions were analyzed by an
ELISA plate and showed a high signal for conformational epitopes (particularly at 2.0 and
1.0 μg of loaded plant VLPs) when compared with a positive loading control, insect cell VLPs
(0.5 μg) (Fig 3D). When ELISA results were further confirmed by immunoblot assay, poly-
clonal antibody (R intact) and a monoclonal antibody recognizing FGA epitope (1H8) detected
an L1 band at 56 kDa, as shown in Fig 3E. However, no L1 protein was detected in either plant
or positive control using HPV16 conformational antibodies (16A and C) which exhibited a
high signal in the ELISA assay, likely because the critical epitope conformation had been lost
under the denaturing conditions (Fig 3E).
In order to optimize the conditions and strategy for collecting the accumulated VLPs, alter-
native purification methods were tested. Using forty-five percent of AMS, most of the L1 pro-
teins and VLPs were successfully recovered. Following each step of the AMS treatment, TSPs
were precipitated and clarified, which drastically reduced the TSPs to one-fifth of 760 mg (152
mg).
These results indicated that more than 75% of TSPs were effectively precipitated; most of
the recovered L1 proteins were soluble in PBS buffer, as shown in Fig 4A. When an additional
step of purification was conducted using SEC, the AMS precipitated L1 proteins showed an
intense (1000 mAU) single symmetric peak with 38–55 mL of elution buffer (Fig 4B), and
Fig 4. Ammonium sulfate precipitation and purification of the V3 infiltrated plants. (A) Immunoblot of
ammonium sulfate precipitated L1 protein samples collected at various stages of purification. 16E monoclonal
antibody was used to detect the target L1 protein. (B) The size exclusion chromatogram for purification of
ammonium sulfate precipitated L1 protein and VLPs using FPLC system. The running profile of molecular
standards, BD; bluedex (2000 kDa), C; conalbumin (75 kDa), O; ovalbumin (43 kDa), CA; carbonic anhydrase (29
kDa) and R; ribonuclease (6.5 kDa) are showed on the chromatogram. (C) Immunoblot showing the detection
profile of fig B and L1 protein was detected in the collected fractions corresponding to 40–50 mL fraction size. (D)
Immunoblot showing the bands of cation exchange chromatography collected L1 protein. Sample (V3) and purified
VLPs from insect cells (PC) were eluted at 0.3 M and 0.7 M NaCl, respectively. The arrows in immunoblots show
HPV L1 band at 56 kDa.
doi:10.1371/journal.pone.0160995.g004
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recovered fractions (# 40–50) showed the presence of the L1 protein revealed by immunoblot
assay (Fig 4C).
Based on the isoelectric point (pI) of 8.5 for the L1 protein, crude extracts, CsCl, and AMS
precipitated protein samples were also subjected to CM Sepharose Fast Flow, a weak cation
exchanger. We found that plant protein samples showed low binding affinity with the cation
column and started eluting early with only 0.3 M of NaCl. Unlike the plant protein, the insect
cell-expressed L1 protein was eluted at 0.7 M NaCl (data not shown). These results were also
verified by immunoblot assay, which showed that most of the plant L1 protein was eluted with-
out being bound and lost during the wash (Fig 4D).
Electron microscopic and immunogenicity analysis of plant VLPs
Our results confirmed that purified HPV16 L1 protein self-assembled into stable VLPs in
plants. As shown in Fig 5A, fractions recovered after SEC and CsCl purification methods were
the best and showed numerous VLPs, predominantly 35–55 nm in size. The top and bottom
bands from the CsCl density gradient contained a lower density of partially purified VLPs.
However, AMS purification followed by SEC gave the highest yield of L1, but an electron
Fig 5. Electronmicrograph and immunogenicity profile of purified plant HPV16 L1 VLPs. Purified (V3) sample (A) and HPV16
VLPs derived from insect cells (A1) were absorbed on carbon coated grid and negatively stained with 2% phospho-tungstic acid (pH
6.8). Magnification was 46,000x; (B) The ELISA profile of hyperimmune sera collected from plant HPV16 L1 VLPs immunized mice. First
two bars show the generated immune response against the sera of unimmunized mice (UM) act as a control and immunized mice with
plant purified HPV16 VLPs, respectively when plant VLPs were loaded as antigens onto ELISA plate. Third and fourth bar represents
the insect cell VLPs response, coated as antigens, against the sera collected from the above unimmunized (UM) and immunized mice
(IM) with plant VLPs, respectively. Student’s t-test was done to compare differences between unimmunized (UM) and immunized mice
(IM) from VLPS of plant extract and insect cells.
doi:10.1371/journal.pone.0160995.g005
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microscopic analysis showed only the presence of L1 capsomers (data not shown). In contrast,
cation exchange collected L1 did not show the formation of VLPs because most of the L1 pro-
tein was lost during the purification process.
To test the immunogenicity of plant VLPs, antibody titers were evaluated in immunized
mice (Fig 5B), where 1:100 diluted sera of mice immunized with the plant VLPs showed high
reactivity with both plant and insect cell VLPs coated plates while no anti-VLP antibody
response was detected in unimmunized mice of both the sets. Also, when plant VLPs immu-
nized sera was titrated against insect cell VLPs, high antibody titers (>3200) was observed.
Discussion
The aim of our study is to successfully express and purify HPV16 L1 VLPs from tobacco plants
using MagnICON expression system. The L1 protein was designed to be accumulated in chlo-
roplasts, which lead to the assembly of predominantly 35–55 nm VLPs with maximal protein
level (>2.5% of TSP).
Low levels of recombinant HPV L1 protein expression lead to decreased formation of VLPs,
which in turn reflects the total outcome yield of purified VLPs [19,24]. Therefore, the nature of
L1 expression and the extent of recovery of the target protein during downstream processing
are important factors that affect costs in the production of biopharmaceuticals based on recom-
binant proteins [25]. With the substantial strides of HPV16 VLPs as a promising vaccine plat-
form [26], the major challenge is to develop production platforms that can deliver VLP-based
vaccine to clinics timely with a reduced price [9]. Although, the development of plant virus-
based transient plant expression systems has overcome the challenges of L1 expression and
yield [27,28], studies to encapsulate HPV VLPs are still in progress.
Compared to nuclear transformation, it has been documented that genetic engineering of
plastids offers many advantages, which make the system ideal for applications involving plant-
made pharmaceuticals [29]. These include high levels of transgene expression because of a
large number of copies, absence of epigenetic effects and transgene containment via maternal
inheritance, and multi-gene expression in a single transformation event [30–32]. Subsequently,
a variety of adjustments was made to increase the yield and expression of proteins in chloro-
plasts. Many vaccine antigens against several human and animal diseases were successfully
expressed in chloroplasts [32]. Recently, HPV16 L1 proteins were successfully expressed in
chloroplasts, although no significant data related to their optimal yield was obtained [13,33].
Accordingly, we used chloroplast transit peptide (TP) in this study to induce L1 expression
with a magnICON vector (p26212). The TP sequence was added to the L1 primary sequence
after eliminating the original nuclear-translocated localization signal (NLS). Therefore, we
have a truncated L1 without 22 amino acids of the C-terminal end that corresponds to the
localization signal. In order to analyze the effect of transition signals, three different vectors
were constructed (p26212-16L1d22, p26212-TPL1d22 and p26212-TPL1F) and compared.
Our approach based on the use of a chloroplast transit peptide and a magnICON expression
vector successfully led to a higher expression and accumulation of VLPs in the chloroplasts of
plant cells.
Expression of L1 proteins was shown in plants transfected with all three constructs upon
extraction with an HEPES buffer [13], and the highest level was exhibited in plants transfected
with the p26212-TPL1F vector. The lowest expression was shown where no transit signal pep-
tide (p26212-16L1d22) was used. Although the cellular mechanism is not clearly understood
for the protein expression process, the existence of any localization signal induced higher yield,
and the existence of both TP and NLS seem to increase the yield. The constructed vector with
full-length L1+TP was the best for L1 protein expression, and therefore, we decided to use the
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p26212-TPL1F vector for L1 expression in plants. However, L1 protein levels in HEPES buffer
extracts of all three vectors were not high enough to continue for VLP purification.
Low yield of L1 in extracts with HEPES buffer suggested that L1 protein might be degraded
during the extraction and homogenization process. To overcome the problem of low yield, we
optimized our extraction protocol using different buffers and salts, and an antioxidant supple-
ment was added to reduce L1 oxidation. Our results indicated that extraction of HPV16 L1
from leaf tissue was most efficient (>2.5% of TSP) with a low-salt phosphate buffer (pH 7.0).
Using this neutral pH phosphate buffer, we found that L1 expression reached the maximum
between 6 and 7 DPI. A study had previously shown that neutral or lower pH aided in the
assembly of T = 1 or T = 7 L1 VLPs [3]. Similarly, our expression level analysis suggested that 6
DPI, with low salt and neutral pH, was the best condition for harvesting and extracting
proteins.
Notably, our improved purification protocol gave higher L1 VLP's recovery with the suc-
cessful removal of major plant proteins such as Ribulose-1,5-bisphosphate carboxylase/oxyge-
nase (RuBisCo) from the purified product. After that, different purification strategies to
intensively recover highly stable and purified VLPs were tested in this study. Therefore, combi-
nations of CsCl density gradient analysis, ammonium sulfate precipitation, and different chro-
matographic purification techniques were employed to remove contaminated proteins and
recover purified ones and eventually to standardize the best conditions for purification. Since
VLPs were only partially purified when a single purification method was used, we used a com-
bination of steps to remove contaminated proteins. The VLPs recovered after the purification
steps were abundant and highly antigenic as evident by electron microscopic and ELISA analy-
sis. Although the HPV-neutralization activity of plant VLP-induced antibodies was not
assessed in the present study, their high binding titers to insect cell-produced VLPs, as shown
in Fig 5B, suggest the efficacy of the plant-made immunogen. To prove this, a study is currently
underway to compare the neutralization activities of sera from mice immunized with insect
cell- and plant-produced VLPs.
Another problem in previous studies was the aggregation of proteins. Therefore, purifica-
tion conditions that maintain the intact conformation of VLPs are important because recombi-
nant VLPs are inherently unstable and tend to denature and aggregate in solution [12, 28]. To
stabilize and protect HPV VLPs from aggregation and concentration loss, a series of commer-
cially available non-ionic surfactants were previously evaluated [34]. As suggested, we used a
minimal amount of polysorbate to increase the storage viability of VLPs and protect against
aggregation. Notably, our experimental conditions proved that the presence of polysorbate 20
at a low concentration of 0.01% and salt conditions (ca. 0.1–0.2M) significantly enhanced the
storage stability of VLPs during all of the purification steps.
AMS was used as an alternative method to purify L1 proteins. In agreement with a previous
study [19], our results suggested that an AMS precipitation step is an effective method for
removal of contaminants with the recovery of most of the soluble L1 proteins prior to the chro-
matography step. However, this method did not produce VLP formation of L1 monomers or
capsomers. Similarly, low amounts of L1 proteins were obtained from the cation column
because most of the L1 protein was washed away during the purification process. It has been
suggested that the interaction between HPV16 VLP and heparin was dependent on a positive
charge distribution. Although we used the cation column instead of a heparin column, a possi-
ble reason for losing the L1 protein could be the low positive charge distribution on its matrix
as proposed by Knappe et al. [35]. More investigation is required to determine the feasibility of
cation exchange chromatography to purify plant-produced L1 VLPs.
In conclusion, we demonstrated that a magnlCON plant virus vector with full-length L1
and a chloroplast transit peptide successfully produced HPV16 L1 VLPs in tobacco plants.
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Extraction of HPV16 L1 from leaf tissue was most efficient (>2.5% of TSP) with a low-salt
phosphate buffer in the presence of HPV16 L1 VLPs, predominantly 35–55 nm in size, evident
from electron microscopic studies. Although we used CsCl density gradient centrifugation as
the preliminary step to remove plant proteins and collect VLPs, these data may be useful for
the development of chloroplast-based vaccines. We anticipate that our new purification meth-
ods described herein will aid in recovering highly antigenic HPV16 VLPs from tobacco plants
towards the goal of reducing time, cost, and labor while increasing the capacity for industrial
production.
Supporting Information
S1 Fig. Detection profile of non-infiltrated tobacco leaves. Immunoblot represents the detec-
tion profile of HPV16 L1 protein where NC; negative control corresponds to non-infiltrated
tobacco leaves, V3; PBS extracted 6 DPI tobacco leaves with V3 construct and PC; positive con-
trol, VLPs derived from insect cells. MoAbs (16E and 1H8) and PoAb (disCPV2) were used to
detect sequential epitopes of HPV16 L1 protein.
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